We are live on
!
Find out more
SGAM
Smith Group Asset Management Portfolio holdings
AUM
$2.46B
1-Year Est. Return
57.16%
This Fund
S&P 500
This Quarter
Est. Return
-14.95%
1 Year Est. Return
+57.16%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.83B
AUM Growth
-$682M
(-19%)
Cap. Flow
-$127M
Cap. Flow
% of AUM
-4.47%
Top 10 Holdings %
Top 10 Hldgs %
29.76%
Holding
486
New
59
Increased
45
Reduced
264
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$30.8M |
| 2 |
TripAdvisor
TRIP
|
+$30.5M |
| 3 |
Estee Lauder
EL
|
+$29.1M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
+$26.3M |
| 5 |
UnitedHealth
UNH
|
+$25.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sysco
SYY
|
+$65.1M |
| 2 |
Intuit
INTU
|
+$48.1M |
| 3 |
Baxter International
BAX
|
+$33.7M |
| 4 |
Hilton Worldwide
HLT
|
+$24.8M |
| 5 |
Salesforce
CRM
|
+$20M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.28% |
| 2 | Healthcare | 16.08% |
| 3 | Consumer Discretionary | 15.15% |
| 4 | Industrials | 13.19% |
| 5 | Financials | 9.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
James River Group Holdings
JRVR
$210M
| $411K | 0.01% |
+11,240
| New | +$428K |
|
|
ARRY
202
DELISTED
Array Biopharma Inc
ARRY
| $389K | 0.01% |
27,320
-600
| -2% | -$9.1K |
|
203
Qualys
QLYS
$6.43B
| $386K | 0.01% |
+5,160
| New | +$389K |
|
204
Emergent Biosolutions
EBS
$229M
| $372K | 0.01% |
6,274
-103
| -2% | -$6.64K |
|
205
Chord Energy
CHRD
$7.58B
| $368K | 0.01% |
66,576
+64,039
| +2,524% | +$581K |
|
206
Travel + Leisure Co
TNL
$4.5B
| $368K | 0.01% |
10,100
| – | – |
|
207
Marcus & Millichap
MMI
$1.16B
| $365K | 0.01% |
10,630
-13,650
| -56% | -$468K |
|
|
CBM
208
DELISTED
Cambrex Corporation
CBM
| $363K | 0.01% |
+9,610
| New | +$486K |
|
209
Ligand Pharmaceuticals
LGND
$5.89B
| $343K | 0.01% |
4,056
-160
| -4% | -$17.1K |
|
210
Tenet Healthcare
THC
$20.9B
| $336K | 0.01% |
19,631
-65,250
| -77% | -$1.58M |
|
|
BSTC
211
DELISTED
BioSpecifics Technologies Corp.
BSTC
| $334K | 0.01% |
5,511
-633
| -10% | -$37.8K |
|
212
First Community Bankshares
FCBC
$903M
| $302K | 0.01% |
9,589
-1,325
| -12% | -$44.2K |
|
|
PES
213
DELISTED
Pioneer Energy Services Corp.
PES
| $302K | 0.01% |
245,230
-6,050
| -2% | -$15.1K |
|
214
Central Pacific Financial
CPF
$991M
| $296K | 0.01% |
+12,140
| New | +$320K |
|
215
Ennis
EBF
$558M
| $292K | 0.01% |
15,168
-20
| -0.1% | -$384 |
|
|
ICPT
216
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $285K | 0.01% |
2,830
-100
| -3% | -$10.4K |
|
217
OFG Bancorp
OFG
$2.2B
| $280K | 0.01% |
16,987
-2,030
| -11% | -$34.2K |
|
218
World Acceptance Corp
WRLD
$871M
| $279K | 0.01% |
2,730
-130
| -5% | -$13.4K |
|
219
Lantheus
LNTH
$6.59B
| $277K | 0.01% |
17,715
-22
| -0.1% | -$337 |
|
220
Tilly's
TLYS
$130M
| $268K | 0.01% |
24,705
-85,770
| -78% | -$1.27M |
|
221
Repligen
RGEN
$9.21B
| $261K | 0.01% |
4,956
-102
| -2% | -$5.98K |
|
222
Ultragenyx Pharmaceutical
RARE
$2.64B
| $260K | 0.01% |
5,970
-100
| -2% | -$5.46K |
|
223
US Physical Therapy
USPH
$1.22B
| $253K | 0.01% |
2,473
-300
| -11% | -$33.3K |
|
|
BPMC
224
DELISTED
Blueprint Medicines
BPMC
| $251K | 0.01% |
4,650
-100
| -2% | -$6.08K |
|
|
CCXI
225
DELISTED
ChemoCentryx, Inc.
CCXI
| $250K | 0.01% |
22,897
-3,550
| -13% | -$37.4K |
|
Similar funds
M
GWM
QT
SCM
TW
KFA
SG
FFA
Smith Group Asset Management's Q4 2018 Portfolio in Review
As of Q4 2018, Smith Group Asset Management held 486 positions worth $2.83B, down 19% from $3.52B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Smith Group Asset Management withdrew a net $127M in Q4 2018, closing 40 positions and reducing 264 holdings. Its most notable exit was Intuit, an estimated $48.1M position sold in full.
By sector, the portfolio is most concentrated in Technology at 29% of assets, down from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Smith Group Asset Management opened a new position in Estee Lauder worth $27.9M.
- Smith Group Asset Management's largest Q4 2018 buy was Estee Lauder: 214,550 shares worth $27.9M.
- Smith Group Asset Management added most to Bristol-Myers Squibb in Q4 2018, an estimated $30.8M increase.
- Smith Group Asset Management's biggest Q4 2018 reduction was Sysco, cutting an estimated $65.1M.
- Smith Group Asset Management fully exited Intuit in Q4 2018, selling an estimated $48.1M.
- Smith Group Asset Management's ten largest holdings make up 30% of its $2.83B portfolio in Q4 2018.
- Smith Group Asset Management opened 59 new positions and closed 40 in Q4 2018.
- Smith Group Asset Management's portfolio value fell 19% quarter-over-quarter to $2.83B.
Based on Smith Group Asset Management's 13F filing for Q4 2018, filed 6 Feb 2019.